Telotristat ethyl
Xermelo (telotristat ethyl) is a small molecule pharmaceutical. Telotristat ethyl was first approved as Xermelo on 2017-09-17. It is used to treat diarrhea and malignant carcinoid syndrome in the USA. It has been approved in Europe to treat carcinoid tumor and neuroendocrine tumors. It is known to target tryptophan 5-hydroxylase 1.
| Trade Name | Xermelo |
|---|---|
| Common Name | Telotristat ethyl |
| Indication | carcinoid tumor, diarrhea, malignant carcinoid syndrome, neuroendocrine tumors |
| Drug Class | Enzyme inhibitors: tryptophan hydroxylase inhibitors |
